From the Journals

Statin use is uniformly low in adults with dyslipidemia disorders


 

FROM CIRCULATION

Despite high rates of awareness, statin use was low across the board. Just over half (52% ) of patients with definite/probable FH were using a statin. The rate of statin use was even lower in patients with severe dyslipidemia, at only 38%. High-intensity statin use also dwindled in both dyslipidemia and FH patient groups (37% and 30%, respectively).

Rates of cholesterol screening, awareness, and lipid-lowering medication were particularly low in younger patients, uninsured patients, and patients without a usual source of care. Among young patients (20-39 years), 62% reported cholesterol screening in the past 5 years and 64% reported being aware of having hypercholesterolemia. Of this group, 13% were on a statin. Uninsured adults fared only slightly better, with nearly a third (29%) undergoing a recent screening and using a statin.

Limitations to the analysis include the self-reported information on cholesterol screening, awareness, treatment rates, and the lack of information concerning statin dosages.

In light of the results of this study, Dr. Bucholz emphasized that statin use among underserved patient groups without access to care needs to be a priority.

Recommended Reading

Adding hypertension in pregnancy doesn’t refine ASCVD risk prediction tool
MDedge Family Medicine
Mild cognitive impairment rises in heart patients with comorbidities
MDedge Family Medicine
Heart attacks soar in young IBD patients
MDedge Family Medicine
Post-ACS death lowered in ODYSSEY Outcomes
MDedge Family Medicine
ODYSSEY Outcomes results build on FOURIER
MDedge Family Medicine
ODYSSEY Outcomes trial redefines secondary cardiovascular prevention
MDedge Family Medicine
Ticagrelor noninferior to clopidogrel in terms of major bleeds in STEMI
MDedge Family Medicine
Genotype did not significantly affect evacetrapib response
MDedge Family Medicine
VIDEO: Researchers closing in on the elusive ‘male pill’
MDedge Family Medicine
SGLT2 inhibitors cut cardiovascular outcomes regardless of region
MDedge Family Medicine